Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IOmet Pharma
Edinburgh, Scotland, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Prior to acquisition, IOmet Pharma had a comprehensive preclinical pipeline focused on developing small molecule inhibitors of IDO1 and TDO for use in cancer immunotherapy and metabolism. No clinical-stage data were disclosed before the company's acquisition by Merck.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
University of DundeeScottish Investment Bank
Beyond the preview
Go deeper on IOmet Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IOmet Pharma.